Staying Up-to-date


Upcoming Events

Latest Press Releases

September 3, 2019

OMEICOS Therapeutics Appoints Dr Simon Russell as Chief Business Officer

Read more
April 29, 2019

OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation

Read more
February 11, 2019

OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter

Read more
November 2, 2018

OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation

Read more
July 17, 2018

OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation

Read more
April 27, 2018

Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics

Read more
November 13, 2017

OMEICOS Announces Formation of Inaugural Clinical Advisory Board

Read more
October 4, 2017

OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology

Read more
June 7, 2017

OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

Read more
March 1, 2017

OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial

Read more
November 2, 2015

OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation

Read more
April 15, 2015

OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation

Read more